Hypoxia regulates CD9 expression and dissemination of B lymphoblasts.

[1]  W. Geldenhuys,et al.  Co-culture model of B-cell acute lymphoblastic leukemia recapitulates a transcription signature of chemotherapy-refractory minimal residual disease , 2021, Scientific Reports.

[2]  M. Okochi,et al.  Inhibition of cancer-cell migration by tetraspanin CD9-binding peptide. , 2021, Chemical communications.

[3]  Yuhong Zhou,et al.  CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP-B15 cells , 2020, Molecular medicine reports.

[4]  M. Arcangeli,et al.  Hypoxia Regulates Lymphoid Development of Human Hematopoietic Progenitors. , 2019, Cell reports.

[5]  Chi-kong Li,et al.  CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity , 2019, Leukemia.

[6]  M. Galibert,et al.  Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues. , 2019, Blood reviews.

[7]  Wei Jiang,et al.  CD9 expression indicates a poor outcome in acute lymphoblastic leukemia. , 2017, Cancer biomarkers : section A of Disease markers.

[8]  H. Kestler,et al.  Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. , 2017, Blood.

[9]  S. Miyano,et al.  Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA. , 2017, Blood.

[10]  M. Konopleva,et al.  Integration of hypoxic HIF-α signaling in blood cancers , 2017, Oncogene.

[11]  J. Ragoussis,et al.  Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics , 2017, Hypoxia.

[12]  W. Hiddemann,et al.  Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia , 2016, Cancer cell.

[13]  P. Kearns,et al.  The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. , 2016, Blood.

[14]  M. Bottai,et al.  Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome , 2016, Haematologica.

[15]  N. Varin‐Blank,et al.  CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling. , 2015, Blood.

[16]  Xue Xu,et al.  Hypoxia regulates CD9-mediated keratinocyte migration via the P38/MAPK pathway , 2014, Scientific Reports.

[17]  Sergei A. Vinogradov,et al.  Direct measurement of local oxygen concentration in the bone marrow of live animals , 2014, Nature.

[18]  A. Zepeda,et al.  The Hypoxic Testicle: Physiology and Pathophysiology , 2012, Oxidative medicine and cellular longevity.

[19]  M. Konopleva,et al.  Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment , 2012, Cancer biology & therapy.

[20]  J. Cayuela,et al.  Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol , 2012, Haematologica.

[21]  Chi-kong Li,et al.  The tetraspanin CD9 regulates migration, adhesion, and homing of human cord blood CD34+ hematopoietic stem and progenitor cells. , 2011, Blood.

[22]  K. Anderson,et al.  Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. , 2009, Blood.

[23]  V. Praloran,et al.  Very low oxygen concentration (0.1%) reveals two FDCP-Mix cell subpopulations that differ by their cell cycling, differentiation and p27KIP1 expression , 2011, Cell Death and Differentiation.

[24]  M. Schrappe,et al.  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Mosser,et al.  CD9 expression can be used to predict childhood TEL/AML1-positive acute lymphoblastic leukemia: proposal for an accelerated diagnostic flowchart. , 2010, Leukemia research.

[26]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[27]  Zoran Ivanovic,et al.  Hypoxia or in situ normoxia: The stem cell paradigm , 2009, Journal of cellular physiology.

[28]  M. Zöller.  Tetraspanins: push and pull in suppressing and promoting metastasis , 2009, Nature Reviews Cancer.

[29]  S. Tsai,et al.  Regulation of CD151 by Hypoxia Controls Cell Adhesion and Metastasis in Colorectal Cancer , 2008, Clinical Cancer Research.

[30]  Jean Mosser,et al.  Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia , 2007, BMC Genomics.